Literature DB >> 8320611

Evaluation of secondary prophylactic schemes, based on benzathine penicillin G, for rheumatic fever in children.

Z M Meira1, C de C Mota, E Tonelli, E A Nunan, A M Mitre, N S Moreira.   

Abstract

Serum concentrations of penicillin were measured in children with rheumatic fever. The adequacy of the values after administration of 1.2 million units of benzathine penicillin G every 2 or 3 weeks was confirmed; the adequacy of a 4-week regimen was questionable. The administration of 0.6 million units every 3 weeks was found to be inadequate to maintain serum levels high enough for the secondary prophylaxis of rheumatic fever.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8320611     DOI: 10.1016/s0022-3476(05)81563-x

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  6 in total

1.  Prophylactic efficiency of 3-weekly benzathine penicillin G in rheumatic fever.

Authors:  B Oran; A Tastekin; S Karaaslan; L Bas; A Ayçiçek; A Ceri; A Sütçü; I Erkul
Journal:  Indian J Pediatr       Date:  2000-03       Impact factor: 1.967

2.  Long term follow up of rheumatic fever and predictors of severe rheumatic valvar disease in Brazilian children and adolescents.

Authors:  Z M A Meira; E M A Goulart; E A Colosimo; C C C Mota
Journal:  Heart       Date:  2005-08       Impact factor: 5.994

Review 3.  Penicillin for secondary prevention of rheumatic fever.

Authors:  J Manyemba; B M Mayosi
Journal:  Cochrane Database Syst Rev       Date:  2002

4.  Rheumatic Fever and Long-term Sequelae in Children.

Authors:  Anita Saxena
Journal:  Curr Treat Options Cardiovasc Med       Date:  2002-08

5.  "MacCallum Plaque of the Heart": A Medicolegal Case.

Authors:  Udasimath Shivakumarswamy; Sankappa P Sinhasan; R Purushotham; K R Nagesha
Journal:  Heart Views       Date:  2010-06

6.  Rheumatic Fever prevention program: long-term evolution and outcomes.

Authors:  Cleonice Carvalho Coelho Mota; Zilda Maria Alves Meira; Rosangela Nicoli Graciano; Fernando Felipe Graciano; Fátima Derlene Rocha Araújo
Journal:  Front Pediatr       Date:  2015-01-06       Impact factor: 3.418

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.